person · Reporting owner

MASSARANY HANY

Disclosed activity across 3 companies

Tapewire entity: 70087
SEC CIK: 0001134554

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Accelerate Diagnostics, IncAXDX · Entity 78156	Director	June 28, 2024	July 01, 2024
BIODESIX INCBDSX · Entity 6053	Director	January 02, 2026	January 06, 2026
GenMark Diagnostics, Inc.GNMK · Entity 140086	Director · President and CEO	January 23, 2020	January 23, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Accelerate Diagnostics, Inc

Report date June 28, 2024 · Filed July 01, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	36,891	Reported balance After 2024-06-28 transaction · row 1 1 source row Row 1 · 2024-06-28 · Exercise / conversion · Acquired 4,737 · Balance 36,891 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	18,947	Reported balance After 2024-06-28 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-06-28 · Exercise / conversion · Disposed 4,737 · Balance 18,947 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting. F2: On June 28, 2023, the reporting person was granted a total of 23,684 RSUs, which vest in five equal annual installments beginning on June 28, 2024.
Common StockSEC Table I · non-derivative	IndirectBy Massarany Family Trust dated November 15, 2012	3,000	Reported balance Holding disclosure · report date 2024-06-28 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 3,000

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting.

F2: On June 28, 2023, the reporting person was granted a total of 23,684 RSUs, which vest in five equal annual installments beginning on June 28, 2024.

BIODESIX INC

Report date January 02, 2026 · Filed January 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	7,484	Reported balance After 2026-01-02 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-01-02 · Grant · Acquired 7,484 · Balance 7,484 F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock"). F2: These RSUs vest in four equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F3: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.46 · Expires 2036-01-01	Direct	6,354	Reported balance After 2026-01-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-01-02 · Grant · Acquired 6,354 · Balance 6,354 F4: This option vests in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock").

F2: These RSUs vest in four equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F3: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer.

F4: This option vests in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer.

GenMark Diagnostics, Inc.

Report date January 23, 2020 · Filed January 23, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	822,174	Ending reported balance After 2020-01-23 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2020-01-23 · Exercise / conversion · Acquired 75,049 · Balance 851,094 Row 2 · 2020-01-23 · Sale · Disposed 28,920 · Balance 822,174 F1: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted market stock units. F2: The price reported is the weighted average price per share. Shares were sold in multiple transactions at prices ranging from $4.80 to $5.12 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price.
Market Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	47,371	Reported balance After 2020-01-23 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-01-23 · Exercise / conversion · Acquired 22,407 · Balance 47,371 F4: The MSUs vest in three equal installments, on each of December 31, 2018, December 31, 2019, and December 31, 2020; provided that, at the end of the second and third annual performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second annual performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index.
Market Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	164,858	Reported balance After 2020-01-23 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-01-23 · Exercise / conversion · Acquired 52,642 · Balance 164,858 F5: The MSUs vest in three equal installments, on each of December 31, 2019, December 31, 2020, and December 31, 2021; provided that, at the end of the second and third performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index.
Common StockSEC Table I · non-derivative	IndirectMassarany Family Trust dated November 15, 2012	524,568	Reported balance Holding disclosure · report date 2020-01-23 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 524,568 F3: Mr. Massarany is the trustee of the Massarany Family Trust and may be deemed to have beneficial ownership of these securities, to the extent of any indirect pecuniary interest in his distributive shares therein.

Filing footnotes · ownership attribution and instrument terms

F1: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted market stock units.

F2: The price reported is the weighted average price per share. Shares were sold in multiple transactions at prices ranging from $4.80 to $5.12 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price.

F3: Mr. Massarany is the trustee of the Massarany Family Trust and may be deemed to have beneficial ownership of these securities, to the extent of any indirect pecuniary interest in his distributive shares therein.

F4: The MSUs vest in three equal installments, on each of December 31, 2018, December 31, 2019, and December 31, 2020; provided that, at the end of the second and third annual performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second annual performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index.

F5: The MSUs vest in three equal installments, on each of December 31, 2019, December 31, 2020, and December 31, 2021; provided that, at the end of the second and third performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 02, 2026 Filed Jan 6, 2026 16:26 UTC	BIODESIX INC BDSX · Entity 6053	GrantStock Options (Right to Buy) · Derivative	6,354	$0.00 Strike: $6.46	$0.00	Disclosure SEC source: 0000905148-26-000071 · form4.xml · derivative · entry 2 MASSARANY HANY · CIK 0001134554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,354 Underlying: Common Stock · 6,354 shares Expires 2036-01-01 F4 · derivative.exercise_date: This option vests in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer. Read SEC document
January 02, 2026 Filed Jan 6, 2026 16:26 UTC	BIODESIX INC BDSX · Entity 6053	GrantRestricted Stock Units · Derivative	7,484	$0.00	$0.00	Disclosure SEC source: 0000905148-26-000071 · form4.xml · derivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,484 Underlying: Common Stock · 7,484 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock"). F2 · derivative.exercise_date: These RSUs vest in four equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F2 · derivative.expiration_date: These RSUs vest in four equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F3 · balance_after: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer. Read SEC document
July 01, 2025 Filed Jul 2, 2025 16:32 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionRestricted Stock Units · Derivative	26,368	$0.00	$0.00	Disclosure SEC source: 0000905148-25-002316 · form4.xml · derivative · entry 3 MASSARANY HANY · CIK 0001134554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,368 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: These fully vested RSUs settled on July 1, 2025, and had no expiration date. F3 · derivative.expiration_date: These fully vested RSUs settled on July 1, 2025, and had no expiration date. Read SEC document
July 01, 2025 Filed Jul 2, 2025 16:32 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionCommon Stock	26,368	Not disclosed	Not disclosed	Disclosure SEC source: 0000905148-25-002316 · form4.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 310,135 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
May 20, 2025 Filed May 22, 2025 16:16 UTC	BIODESIX INC BDSX · Entity 6053	GrantStock Options (Right to Buy) · Derivative	42,010	$0.00 Strike: $0.27	$0.00	Disclosure SEC source: 0000905148-25-001895 · form4.xml · derivative · entry 2 MASSARANY HANY · CIK 0001134554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,010 Underlying: Common Stock · 42,010 shares Expires 2035-05-19 F4 · derivative.exercise_date: This option will vest in three substantially equal installments on June 30, September 30 and December 31, 2025, generally subject to the Reporting Person's continued service with the Issuer. Read SEC document
May 20, 2025 Filed May 22, 2025 16:16 UTC	BIODESIX INC BDSX · Entity 6053	GrantRestricted Stock Units · Derivative	86,477	$0.00	$0.00	Disclosure SEC source: 0000905148-25-001895 · form4.xml · derivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,477 Underlying: Common Stock · 86,477 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock"). F2 · derivative.exercise_date: These RSUs will vest in three substantially equal installments on June 30, September 30 and December 31, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F2 · derivative.expiration_date: These RSUs will vest in three substantially equal installments on June 30, September 30 and December 31, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F3 · balance_after: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer. Read SEC document
November 05, 2024 Filed Nov 6, 2024 15:15 UTC	BIODESIX INC BDSX · Entity 6053	PurchaseCommon Stock	22,500	$1.37	$30,865.50	Disclosure SEC source: 0000905148-24-002947 · form4.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Massarany Family Trust dated November 15, 2012 Disclosed balance after: 53,364 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.355 to $1.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Mr. Massarany is a trustee of the Massarany Family Trust and may be deemed to have beneficial ownership of these securities, to the extent of any indirect pecuniary interest in his distributive shares therein. Read SEC document
June 28, 2024 Filed Jul 1, 2024 18:32 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	Exercise / conversionRestricted Stock Units · Derivative	4,737	$0.00	$0.00	Disclosure SEC source: 0001104659-24-076961 · tm2418614-3_4seq1.xml · derivative · entry 3 MASSARANY HANY · CIK 0001134554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,947 Underlying: Common Stock · 4,737 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting. F2 · derivative.exercise_date: On June 28, 2023, the reporting person was granted a total of 23,684 RSUs, which vest in five equal annual installments beginning on June 28, 2024. F2 · derivative.expiration_date: On June 28, 2023, the reporting person was granted a total of 23,684 RSUs, which vest in five equal annual installments beginning on June 28, 2024. Read SEC document
June 28, 2024 Filed Jul 1, 2024 18:32 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	Exercise / conversionCommon Stock	4,737	$0.00	$0.00	Disclosure SEC source: 0001104659-24-076961 · tm2418614-3_4seq1.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,891 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting. Read SEC document
May 29, 2024 Filed May 30, 2024 16:16 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	Exercise / conversionRestricted Stock Units · Derivative	7,894	$0.00	$0.00	Disclosure SEC source: 0001104659-24-066659 · tm2415918-2_4seq1.xml · derivative · entry 3 MASSARANY HANY · CIK 0001134554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,894 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting. F2 · derivative.exercise_date: On May 29, 2023, the reporting person was granted a total of 7,894 RSUs, which vested on the first-year anniversary of the grant date. F2 · derivative.expiration_date: On May 29, 2023, the reporting person was granted a total of 7,894 RSUs, which vested on the first-year anniversary of the grant date. Read SEC document
May 29, 2024 Filed May 30, 2024 16:16 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	Exercise / conversionCommon Stock	7,894	$0.00	$0.00	Disclosure SEC source: 0001104659-24-066659 · tm2415918-2_4seq1.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,154 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting. Read SEC document
May 21, 2024 Filed May 23, 2024 19:14 UTC	BIODESIX INC BDSX · Entity 6053	GrantStock Options (Right to Buy) · Derivative	37,050	$0.00 Strike: $1.57	$0.00	Disclosure SEC source: 0000905148-24-001611 · form4.xml · derivative · entry 2 MASSARANY HANY · CIK 0001134554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,050 Underlying: Common Stock · 37,050 shares Expires 2034-05-20 F4 · derivative.exercise_date: This option will vest in full on March 31, 2025, generally subject to the Reporting Person's continued service with the Issuer. In the event the Reporting Person's continued service on the Board terminates other than for cause, this option will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. Read SEC document
May 21, 2024 Filed May 23, 2024 19:14 UTC	BIODESIX INC BDSX · Entity 6053	GrantRestricted Stock Units · Derivative	57,246	$0.00	$0.00	Disclosure SEC source: 0000905148-24-001611 · form4.xml · derivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,246 Underlying: Common Stock · 57,246 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock"). F2 · derivative.exercise_date: These RSUs will vest in full on March 31, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F2 · derivative.expiration_date: These RSUs will vest in full on March 31, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F3 · balance_after: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer. Read SEC document
May 20, 2024 Filed May 21, 2024 18:57 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	GrantRestricted Stock Units · Derivative	66,667	$0.00	$0.00	Disclosure SEC source: 0001104659-24-063959 · tm2415084-1_4seq1.xml · derivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,667 Underlying: Common Stock · 66,667 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting. F2 · derivative.exercise_date: On May 20, 2024, the reporting person was granted a total of 66,667 RSUs, which vest on the first-year anniversary of the grant date, unless the reporting person leaves in good standing before such vesting date, in which case the RSUs will vest pro-rata based on months served. F2 · derivative.expiration_date: On May 20, 2024, the reporting person was granted a total of 66,667 RSUs, which vest on the first-year anniversary of the grant date, unless the reporting person leaves in good standing before such vesting date, in which case the RSUs will vest pro-rata based on months served. Read SEC document
January 23, 2024 Filed Jan 25, 2024 16:10 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	PurchaseCommon Stock Warrants (right to buy) · Derivative	16,666	Not disclosed Strike: $1.65	Not disclosed	Disclosure SEC source: 0001104659-24-006672 · tm244005-2_4seq1.xml · derivative · entry 3 MASSARANY HANY · CIK 0001134554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,666 Underlying: Common Stock · 16,666 shares Expires 2029-01-23 F1 · price: The reported securities are included within 16,666 units of the issuer (the "Units") purchased by the reporting person for $1.50 per Unit in an underwritten public offering. Each Unit consists of one share of the issuer's common stock and one warrant to purchase one share of the issuer's common stock. Read SEC document
January 23, 2024 Filed Jan 25, 2024 16:10 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	PurchaseCommon Stock	16,666	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-24-006672 · tm244005-2_4seq1.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,260 F1 · price: The reported securities are included within 16,666 units of the issuer (the "Units") purchased by the reporting person for $1.50 per Unit in an underwritten public offering. Each Unit consists of one share of the issuer's common stock and one warrant to purchase one share of the issuer's common stock. Read SEC document
January 01, 2024 Filed Jan 3, 2024 16:16 UTC	BIODESIX INC BDSX · Entity 6053	GrantRestricted Stock Units · Derivative	105,389	$0.00	$0.00	Disclosure SEC source: 0000905148-24-000042 · form4.xml · derivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,924 Underlying: Common Stock · 105,389 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: These RSUs will vest in full on March 31, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F2 · derivative.expiration_date: These RSUs will vest in full on March 31, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F3 · balance_after: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer. Read SEC document
August 03, 2023 Filed Aug 7, 2023 17:31 UTC	BIODESIX INC BDSX · Entity 6053	GrantCommon Stock	30,864	$1.62	$49,999.68	Disclosure SEC source: 0000905148-23-000624 · form4.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Massarany Family Trust dated November 15, 2012 Disclosed balance after: 30,864 F1 · ownership.nature: Mr. Massarany is a trustee of the Massarany Family Trust and may be deemed to have beneficial ownership of these securities, to the extent of any indirect pecuniary interest in his distributive shares therein. Read SEC document
June 28, 2023 Filed Jun 29, 2023 18:03 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	GrantEmployee Restricted Stock Units · Derivative	236,842	$0.00	$0.00	Disclosure SEC source: 0001628280-23-023941 · wk-form4_1688076170.xml · derivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 236,842 Underlying: Common Stock · 236,842 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: On June 28, 2023, the reporting person was granted RSUs which vest in equal amounts each year for 5 years, with the first installment vesting on June 28, 2024. F3 · derivative.expiration_date: Not applicable. Read SEC document
May 31, 2023 Filed Jun 1, 2023 20:30 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	Exercise / conversionEmployee Restricted Stock Units · Derivative	75,949	$0.00	$0.00	Disclosure SEC source: 0001628280-23-020597 · wk-form4_1685665801.xml · derivative · entry 3 MASSARANY HANY · CIK 0001134554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,949 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. On May 31, 2022, the reporting person was granted a total of 75,949 RSUs, which vested in full on May 31, 2023. F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. On May 31, 2022, the reporting person was granted a total of 75,949 RSUs, which vested in full on May 31, 2023. F1 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. On May 31, 2022, the reporting person was granted a total of 75,949 RSUs, which vested in full on May 31, 2023. Read SEC document
May 31, 2023 Filed Jun 1, 2023 20:30 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	Exercise / conversionCommon Stock	75,949	$0.00	$0.00	Disclosure SEC source: 0001628280-23-020597 · wk-form4_1685665801.xml · nonDerivative · entry 2 MASSARANY HANY · CIK 0001134554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,949 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. On May 31, 2022, the reporting person was granted a total of 75,949 RSUs, which vested in full on May 31, 2023. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. On May 31, 2022, the reporting person was granted a total of 75,949 RSUs, which vested in full on May 31, 2023. Read SEC document
May 29, 2023 Filed Jun 1, 2023 18:29 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	GrantEmployee Restricted Stock Units · Derivative	78,947	$0.00	$0.00	Disclosure SEC source: 0001628280-23-020568 · wk-form4_1685658532.xml · derivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,947 Underlying: Common Stock · 78,947 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: On May 29, 2023, the reporting person was granted RSUs. All of the RSUs shall vest on the first-year anniversary of the Date of Grant (the "Vesting Date"), unless Grantee leaves in good standing before 12 months, in which case they will vest pro-rata based on months served. F3 · derivative.expiration_date: Not applicable. Read SEC document
May 23, 2023 Filed May 25, 2023 18:21 UTC	BIODESIX INC BDSX · Entity 6053	GrantRestricted Stock Units · Derivative	37,535	$0.00	$0.00	Disclosure SEC source: 0001140361-23-026714 · form4.xml · derivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,535 Underlying: Common Stock · 37,535 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · shares: The Compensation Committee of the Issuer's Board of Directors also approved a grant to the Reporting Person, effective January 1, 2024, of an additional 105,389 RSUs that will vest in full on March 31, 2024, generally subject to the Reporting Person's continued service with the Issuer. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F2 · derivative.exercise_date: These RSUs will vest in full on March 31, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F2 · derivative.expiration_date: These RSUs will vest in full on March 31, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F4 · derivative.underlying_shares: The Compensation Committee of the Issuer's Board of Directors also approved a grant to the Reporting Person, effective January 1, 2024, of an additional 105,389 RSUs that will vest in full on March 31, 2024, generally subject to the Reporting Person's continued service with the Issuer. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F3 · balance_after: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer. F4 · balance_after: The Compensation Committee of the Issuer's Board of Directors also approved a grant to the Reporting Person, effective January 1, 2024, of an additional 105,389 RSUs that will vest in full on March 31, 2024, generally subject to the Reporting Person's continued service with the Issuer. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. Read SEC document
March 31, 2023 Filed Apr 4, 2023 16:39 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionRestricted Stock Units · Derivative	145,833	$0.00	$0.00	Disclosure SEC source: 0001140361-23-016265 · form4.xml · derivative · entry 2 MASSARANY HANY · CIK 0001134554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,707 Underlying: Common Stock · 145,833 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: These RSUs vested in full on March 31, 2023. F2 · derivative.expiration_date: These RSUs vested in full on March 31, 2023. F3 · balance_after: This amount includes 6,707 deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service to the Issuer. Read SEC document
March 31, 2023 Filed Apr 4, 2023 16:39 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionCommon Stock	145,833	Not disclosed	Not disclosed	Disclosure SEC source: 0001140361-23-016265 · form4.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 283,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
January 03, 2023 Filed Jan 5, 2023 16:31 UTC	BIODESIX INC BDSX · Entity 6053	GrantRestricted Stock Units · Derivative	6,707	$0.00	$0.00	Disclosure SEC source: 0001140361-23-000669 · form4.xml · derivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,540 Underlying: Common Stock · 6,707 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: These RSUs will vest in full on March 31, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F2 · derivative.expiration_date: These RSUs will vest in full on March 31, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F3 · balance_after: This amount includes 6,707 deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service to the Issuer. Read SEC document
January 01, 2023 Filed Jan 4, 2023 18:20 UTC	BIODESIX INC BDSX · Entity 6053	GrantRestricted Stock Units · Derivative	62,500	$0.00	$0.00	Disclosure SEC source: 0001140361-23-000518 · form4.xml · derivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,833 Underlying: Common Stock · 62,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: These RSUs will vest in full on March 31, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F2 · derivative.expiration_date: These RSUs will vest in full on March 31, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. Read SEC document
November 21, 2022 Filed Nov 21, 2022 18:03 UTC	BIODESIX INC BDSX · Entity 6053	PurchaseCommon Stock	130,434	$1.15	$149,999.10	Disclosure SEC source: 0001140361-22-042604 · form4.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,934 Read SEC document
May 31, 2022 Filed Jun 2, 2022 16:20 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	GrantEmployee Restricted Stock Units · Derivative	75,949	$0.00	$0.00	Disclosure SEC source: 0001628280-22-016059 · wf-form4_165420122522746.xml · derivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,949 Underlying: Common Stock · 75,949 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vest in full on May 31, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F3 · derivative.expiration_date: Not applicable. Read SEC document
May 24, 2022 Filed May 26, 2022 16:15 UTC	BIODESIX INC BDSX · Entity 6053	GrantRestricted Stock Units · Derivative	83,333	$0.00	$0.00	Disclosure SEC source: 0001140361-22-020787 · form4.xml · derivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,333 Underlying: Common Stock · 83,333 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock and has no expiration date. F3 · shares: The Compensation Committee of the Issuer's Board of Directors also approved a grant to the Reporting Person, effective January 1, 2023, of an additional 62,500 RSUs that will vest in full on March 31, 2023, generally subject to the reporting person's continued service with the Issuer. In the event the reporting person's continued service on the Board terminates other than for cause, the option will vest on a prorated basis based on the number of full months of service the reporting person completed during the applicable vesting period. F2 · derivative.exercise_date: These RSUs will vest in full on March 31, 2023, generally subject to the reporting person's continued service with the Issuer. In the event the reporting person's continued service on the Board terminates other than for cause, the option will vest on a prorated basis based on the number of full months of service the reporting person completed during the applicable vesting period. F2 · derivative.expiration_date: These RSUs will vest in full on March 31, 2023, generally subject to the reporting person's continued service with the Issuer. In the event the reporting person's continued service on the Board terminates other than for cause, the option will vest on a prorated basis based on the number of full months of service the reporting person completed during the applicable vesting period. F3 · derivative.underlying_shares: The Compensation Committee of the Issuer's Board of Directors also approved a grant to the Reporting Person, effective January 1, 2023, of an additional 62,500 RSUs that will vest in full on March 31, 2023, generally subject to the reporting person's continued service with the Issuer. In the event the reporting person's continued service on the Board terminates other than for cause, the option will vest on a prorated basis based on the number of full months of service the reporting person completed during the applicable vesting period. F3 · balance_after: The Compensation Committee of the Issuer's Board of Directors also approved a grant to the Reporting Person, effective January 1, 2023, of an additional 62,500 RSUs that will vest in full on March 31, 2023, generally subject to the reporting person's continued service with the Issuer. In the event the reporting person's continued service on the Board terminates other than for cause, the option will vest on a prorated basis based on the number of full months of service the reporting person completed during the applicable vesting period. Read SEC document
January 31, 2022 Filed Feb 1, 2022 18:05 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	PurchaseCommon Stock	20,000	$3.30	$66,000.00	Disclosure SEC source: 0001628280-22-001586 · wf-form4_164375674159436.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Massarany Family Trust dated November 15, 2012 Disclosed balance after: 30,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.18 to $3.35, inclusive. The reporting person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. F2 · ownership.nature: Mr. Massarany is a trustee of the Massarany Family Trust and may be deemed to have beneficial ownership of these securities, to the extent of any indirect pecuniary interest in his distributive shares therein. Read SEC document
September 27, 2021 Filed Sep 28, 2021 15:46 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	PurchaseCommon Stock	10,000	$5.30	$53,000.00	Disclosure SEC source: 0001628280-21-019223 · wf-form4_163285836756524.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Massarany Family Trust dated November 15, 2012 Disclosed balance after: 10,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.29 to $5.32, inclusive. The reporting person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. F2 · ownership.nature: Mr. Massarany is a trustee of the Massarany Family Trust and may be deemed to have beneficial ownership of these securities, to the extent of any indirect pecuniary interest in his distributive shares therein. Read SEC document
June 29, 2021 Filed Jul 1, 2021 18:23 UTC	BIODESIX INC BDSX · Entity 6053	GrantStock Options (Right to buy) · Derivative	25,789	$0.00 Strike: $13.72	$0.00	Disclosure SEC source: 0000905148-21-000538 · form4.xml · derivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,789 Underlying: Common Stock · 25,789 shares Expires 2031-06-28 F1 · derivative.exercise_date: This option will vest in full on March 31, 2022. Read SEC document
May 20, 2021 Filed May 24, 2021 21:59 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	GrantStock Option (right to buy) · Derivative	31,261	$0.00 Strike: $7.68	$0.00	Disclosure SEC source: 0001104659-21-071494 · tm2117458d3_form4.xml · derivative · entry 2 MASSARANY HANY · CIK 0001134554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,261 Underlying: Common Stock · 31,261 shares Expires 2031-05-20 F2 · derivative.exercise_date: The option vests in full on May 20, 2022. Read SEC document
May 20, 2021 Filed May 24, 2021 21:59 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	GrantStock Option (right to buy) · Derivative	93,783	$0.00 Strike: $7.68	$0.00	Disclosure SEC source: 0001104659-21-071494 · tm2117458d3_form4.xml · derivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,783 Underlying: Common Stock · 93,783 shares Expires 2031-05-20 F1 · derivative.exercise_date: The option vests in five equal annual installments beginning on May 20, 2022. Read SEC document
October 30, 2020 Filed Nov 3, 2020 18:22 UTC	BIODESIX INC BDSX · Entity 6053	PurchaseCommon Stock	7,500	$18.00	$135,000.00	Disclosure SEC source: 0001209191-20-056745 · doc4.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Read SEC document
July 01, 2020 Filed Nov 3, 2020 18:22 UTC	BIODESIX INC BDSX · Entity 6053	GrantRestricted Stock Units · Derivative	26,368	$0.00 Strike: $6.83	$0.00	Disclosure SEC source: 0001209191-20-056745 · doc4.xml · derivative · entry 3 MASSARANY HANY · CIK 0001134554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,368 Underlying: Common Stock · 26,368 shares Expires 2030-06-30 F1 · date: This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F1 · kind: This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F3 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer Common Stock ("Common Stock"). These RSUs vest 40% on July 1, 2022, and the remaining 60% in 36 successive, equal monthly installments measured from July 1, 2022. Read SEC document
July 01, 2020 Filed Nov 3, 2020 18:22 UTC	BIODESIX INC BDSX · Entity 6053	GrantStock Options (Right to buy) · Derivative	35,158	$0.00 Strike: $6.83	$0.00	Disclosure SEC source: 0001209191-20-056745 · doc4.xml · derivative · entry 2 MASSARANY HANY · CIK 0001134554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,158 Underlying: Common Stock · 35,158 shares Expires 2030-06-30 F1 · date: This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F1 · kind: This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F2 · derivative.exercise_date: This option vests in 12 successive, equal monthly installments measured from July 1, 2020. Read SEC document
January 23, 2020 Filed Jan 23, 2020 18:32 UTC	GenMark Diagnostics, Inc. GNMK · Entity 140086	Exercise / conversionMarket Stock Units · Derivative	52,642	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001487371-20-000010 · wf-form4_157982231527226.xml · derivative · entry 5 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,858 Underlying: Common Stock · 52,642 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The MSUs vest in three equal installments, on each of December 31, 2019, December 31, 2020, and December 31, 2021; provided that, at the end of the second and third performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index. F5 · derivative.expiration_date: The MSUs vest in three equal installments, on each of December 31, 2019, December 31, 2020, and December 31, 2021; provided that, at the end of the second and third performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index. Read SEC document
January 23, 2020 Filed Jan 23, 2020 18:32 UTC	GenMark Diagnostics, Inc. GNMK · Entity 140086	Exercise / conversionMarket Stock Units · Derivative	22,407	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001487371-20-000010 · wf-form4_157982231527226.xml · derivative · entry 4 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,371 Underlying: Common Stock · 22,407 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The MSUs vest in three equal installments, on each of December 31, 2018, December 31, 2019, and December 31, 2020; provided that, at the end of the second and third annual performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second annual performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index. F4 · derivative.expiration_date: The MSUs vest in three equal installments, on each of December 31, 2018, December 31, 2019, and December 31, 2020; provided that, at the end of the second and third annual performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second annual performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index. Read SEC document
January 23, 2020 Filed Jan 23, 2020 18:32 UTC	GenMark Diagnostics, Inc. GNMK · Entity 140086	SaleCommon Stock	28,920	$4.90	$141,708.00	Disclosure SEC source: 0001487371-20-000010 · wf-form4_157982231527226.xml · nonDerivative · entry 2 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 822,174 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted market stock units. F2 · price: The price reported is the weighted average price per share. Shares were sold in multiple transactions at prices ranging from $4.80 to $5.12 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document
January 23, 2020 Filed Jan 23, 2020 18:32 UTC	GenMark Diagnostics, Inc. GNMK · Entity 140086	Exercise / conversionCommon Stock	75,049	$0.00	$0.00	Disclosure SEC source: 0001487371-20-000010 · wf-form4_157982231527226.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 851,094 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 25, 2019 Filed Nov 26, 2019 17:02 UTC	GenMark Diagnostics, Inc. GNMK · Entity 140086	SaleCommon Stock	16,423	$5.43	$89,176.89	Disclosure SEC source: 0001487371-19-000267 · wf-form4_157480573998340.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 776,045 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document
November 20, 2019 Filed Nov 21, 2019 16:54 UTC	GenMark Diagnostics, Inc. GNMK · Entity 140086	SaleCommon Stock	7,744	$5.55	$42,979.20	Disclosure SEC source: 0001487371-19-000249 · wf-form4_157437327699383.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 792,468 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document
August 27, 2019 Filed Aug 30, 2019 19:02 UTC	GenMark Diagnostics, Inc. GNMK · Entity 140086	SaleCommon Stock	16,659	$6.03	$100,453.77	Disclosure SEC source: 0001487371-19-000218 · wf-form4_156720614076127.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800,212 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document
August 20, 2019 Filed Aug 21, 2019 17:02 UTC	GenMark Diagnostics, Inc. GNMK · Entity 140086	SaleCommon Stock	8,080	$6.25	$50,500.00	Disclosure SEC source: 0001487371-19-000198 · wf-form4_156642130781714.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 816,871 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document
May 30, 2019 Filed May 31, 2019 16:24 UTC	GenMark Diagnostics, Inc. GNMK · Entity 140086	SaleCommon Stock	10,369	$6.60	$68,435.40	Disclosure SEC source: 0001487371-19-000143 · wf-form4_155933427829479.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 824,951 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document
May 24, 2019 Filed May 28, 2019 16:34 UTC	GenMark Diagnostics, Inc. GNMK · Entity 140086	SaleCommon Stock	6,247	$6.62	$41,355.14	Disclosure SEC source: 0001487371-19-000137 · wf-form4_155907568278010.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 835,320 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document
May 21, 2019 Filed May 22, 2019 17:05 UTC	GenMark Diagnostics, Inc. GNMK · Entity 140086	SaleCommon Stock	7,837	$6.83	$53,526.71	Disclosure SEC source: 0001487371-19-000119 · wf-form4_155855913930592.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 841,567 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document
February 25, 2019 Filed Feb 27, 2019 16:37 UTC	GenMark Diagnostics, Inc. GNMK · Entity 140086	SaleCommon Stock	54,596	$6.79	$370,706.84	Disclosure SEC source: 0001487371-19-000070 · wf-form4_155130342304464.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 849,404 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. F2 · price: The price reported is the weighted average price per share. Shares were sold in multiple transactions at prices ranging from $6.78 to $7.08 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.